血脂康对原发性高脂血症的临床疗效

为研究血脂康的降脂作用强度，对１０８例原发性高脂血症患者，按血脂水平分层配对随机分组，５３例服血脂康，５５例服辛伐他丁作为对照。８周末两组血清总胆固醇（ＴＣ）分别下降２３．０％与２３．３％，低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）分别下降２８．０％与２９．５％，甘油三酯（ＴＧ）分别下降２８．１％与２９．５％。各自与治疗前相比差异均有显著性（Ｐ均＜０．００１），但两组间对比差异无显著性（Ｐ均＞０．０５）。血脂康耐受性好，无明显不良反应。提示血脂康是与辛伐他丁疗效相似的国产高效血脂调节剂。

EFFECT OF XUEZHIKANG ON THE TREATMENT OF PRIMARY HYPERLIPIDEMIA

Xuezhikang is a new blood lipid regulating medicine. The components of Xuezhikang include HMG CoA reductase inhibitor (lovastatin), unsaturated fatty acids and many kinds of amino acids. A comparative study on the effects of Xuezhikang and Simvastatin (Zocor) was carried out. One hundred and eight patients with primary hyperlipidemia were rondomly divided into two groups. Group 1 consisted of 53 patients, each taking 4 Xuezhikang capsules/day (1.2 g/day) for 8 weeks and group 2 included 55 cases, each taking Zocor 10mg/day for 8 weeks. At the end of 8 weeks, the lipid levels were compared with those of the baseline in each group. In group 1 serum levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL C) and triglycerides (TG) were decreased by 23.0%, 28.0% and 28.1% ( P <0.001) respectively and in group 2 they were reduced by 23.3%, 29.5% and 29.5% ( P <0.001) respectively. Serum level of high density lipoprotein (HDL C) was increased by 5.0% ( P >0.05) with Xuezhikang and 14.3% ( P <0.01) with Zocor, but no significant differences were found between the two groups in TC, LDL C, TG and HDL C. The side effects of Xuezhikang were less than those of Zocor. It is suggested that Xuezhikang made in China is a safe, effective and tolerable lipid modulator.